126 related articles for article (PubMed ID: 10101596)
1. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status.
Niwa K; Murase T; Morishita S; Hashimoto M; Itoh N; Tamaya T
Cancer Detect Prev; 1999; 23(2):147-54. PubMed ID: 10101596
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
3. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
4. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.
Maeda K; Tsuda H; Hashiguchi Y; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2002 Apr; 33(4):386-91. PubMed ID: 12055672
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
6. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
7. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
[TBL] [Abstract][Full Text] [Related]
8. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
10. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
Soong R; Knowles S; Williams KE; Hammond IG; Wysocki SJ; Iacopetta BJ
Br J Cancer; 1996 Aug; 74(4):562-7. PubMed ID: 8761370
[TBL] [Abstract][Full Text] [Related]
12. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
14. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
15. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
16. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
Backe J; Gassel AM; Hauber K; Krebs S; Bartek J; Caffier H; Kreipe HH; Müller-Hermelink HK; Dietl J
Int J Gynecol Pathol; 1997 Oct; 16(4):361-8. PubMed ID: 9421076
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes.
Kalogiannidis I; Bobos M; Papanikolaou A; Makedos A; Amplianitis I; Vergote I; Nenopoulou E; Makedos G
Eur J Gynaecol Oncol; 2008; 29(1):19-25. PubMed ID: 18386458
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma.
Vang R; Barner R; Wheeler DT; Strauss BL
Int J Gynecol Pathol; 2004 Jul; 23(3):223-33. PubMed ID: 15213598
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]